The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
https://apps.who.int/iris/bitstream/handle/10665/331976/WHO-2019-nCoV-Ethics_criteria-2020.1-eng.pdf?ua=1
bottom of page 12 mentions that solidarity trial may work in cooperation with human challenge study, this may speed things up a bit.
sorry Brasso didn't realise you had already posted the same.
Great find by Mark10101 on advfn.
https://apps.who.int/iris/bitstream/handle/10665/331976/WHO-2019-nCoV-Ethics_criteria-2020.1-eng.pdf?ua=1
note the link at bottom of page14 refers to hvivo trial from last year.
hvivo are the world leaders in this field and no doubt will play a huge role in this going forward.
I wonder if the anti viral drug that we are testing for Nearmedic is Kagocel.
https://www.nearmedic.ru/products/kagocel/
woodfromthetrees - Filtered for being a Plank
Trek - filtered for being a pratt.
Trek - Mologic are not in the consortium
It's going to be a good day today.
Might be under the radar here, but big pharma know all about them, taken from FAB website;
The Company has an international, blue-chip client base, which includes eight of the top ten global pharmaceutical companies by revenue. A significant amount of the Company's revenue is generated from follow on service requests from existing clients, providing good visibility of future earnings.
Think a lot of people have missed this one , FAB working with Queens University Belfast on covid 19 in the Coronavirus Antibody Development Alliance : This news has not been released as yet by FAB as far as i know.
New research alliance to seek new therapeutic and diagnostic approaches
Share
Fusion Antibodies, pre-clinical antibody discovery, engineering and supply experts, have established a new research alliance with Queen’s to seek new therapeutic and diagnostic approaches to help in the global fight against the coronavirus pandemic.
The Northern Ireland Coronavirus Antibody Development Alliance (NICADA) aims to develop new therapeutic molecules that can be evaluated for their ability to neutralize SARS-CoV-2, the virus that causes COVID-19 disease.
Working with Professor Ultan Power in the Wellcome-Wolfson Institute of Experimental Medicine, Professor Chris Scott in The Patrick G Johnston Centre for Cancer Research and Dr Fuquan Lui in the School of Biological Sciences, at Queen’s University, Fusion Antibodies will prepare potential antibodies and engineer them specifically to neutralise the virus.
There is a shortage of key reagents for testing globally and although not a core service currently offered by the company, Fusion Antibodies will be using their expertise to develop key reagents that can be employed in the global challenge of COVID-19 testing.
Paul Kerr, CEO, Fusion Antibodies said:
“We are delighted to be able to assist in the global battle against Coronavirus. In the first instance we’ll work with Queen’s University Belfast to provide the key reagent which will be used for testing. Our expertise is focused on antibody development and we’ve already begun the process of engineering antibodies against COVID-19 using our advanced technology platforms.”
Professor Chris Scott, Director of the Patrick G Johnston Cancer Centre, Queen’s University Belfast, said
“By bringing together diverse researchers from virology, biological sciences and cancer research we are rapidly contributing to the development of new reagents that could not only neutralize the virus, but also aid diagnostic efforts; both of which are needed to inform decisions on lifting the current lockdown. We are delighted to initiate this alliance with Fusion Antibodies and to direct our research capabilities towards tackling this global pandemic”.
Ultan Power, Professor of Molecular Virology, Queen’s University Belfast said:
"The NICADA alliance provides an excellent opportunity to generate novel therapeutics and diagnostics to help the global fight against SARS-CoV-2.”
The NICADA alliance is actively harnessing the best scientific talent to tackle the global coronavirus pandemic.
For more information about Queen's work in response to the coronavirus, visit: hxxps://www.qub.ac.uk/coronavirus/
Ventilators from Israel to be shipped by air to speed up delivery.
https://translate.google.com/translate?hl=en&sl=iw&u=https://www.israelhayom.co.il/article/746699&prev=search